Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia—a real-world analysis of the Polish Adult Leukemia Study Group

The results of the MURANO trial showed encouraging progression-free survival (PFS) and overall survival (OS) in relapsed/refractory chronic lymphocytic leukemia (RR-CLL) patients treated with venetoclax-rituximab (VEN-R). A retrospective analysis was performed to evaluate the efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Soboń, Anita, Drozd-Sokołowska, Joanna, Paszkiewicz-Kozik, Ewa, Popławska, Lidia, Morawska, Marta, Tryc-Szponder, Jagoda, Bołkun, Łukasz, Rybka, Justyna, Pruszczyk, Katarzyna, Juda, Adrian, Majeranowski, Alan, Iskierka-Jażdżewska, Elżbieta, Steckiewicz, Paweł, Wdowiak, Kamil, Budziszewska, Bożena, Jamroziak, Krzysztof, Hus, Iwona, Lech-Marańda, Ewa, Puła, Bartosz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344985/
https://www.ncbi.nlm.nih.gov/pubmed/37392368
http://dx.doi.org/10.1007/s00277-023-05304-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344985/
https://www.ncbi.nlm.nih.gov/pubmed/37392368
http://dx.doi.org/10.1007/s00277-023-05304-4

Ejemplares similares